The rising use of weight-loss injections is expected to significantly reduce alcohol consumption and alter supermarket retail strategies, according to industry analysts. As drugs like Moujnaro and Wegovy become more popular, shoppers reportedly are drinking less, prompting retailers to rethink shelf space and promotional efforts for alcoholic beverages.

Clive Black, a retail analyst at Shore Capital, said the expanding uptake of such weight-loss treatments will lead supermarkets to allocate less space to alcohol. “There will be fewer promotions of booze in stores because, frankly, why promote it if people are going to drink less?” Black said. He added that the traditional supermarket scenario of aisles stacked with discounted beer and wine cartons is likely coming to an end.

This assessment aligns with findings from a YouGov survey, which indicated that 39 percent of individuals using weight-loss drugs have reduced their alcohol intake. Black noted that as weight-loss tablets become available alongside injection treatments, the decline in alcohol consumption is expected to accelerate further. “As tablets replace jabs, this is going to go through two or three gears. It’s here to stay,” he said.

The broader impact on alcohol sales is expected to be significant, with Black suggesting declines could be seen globally. However, he also noted that premium retailers might experience a lesser effect, given their focus on higher-end products and different consumer behaviors.

The shift comes amid a growing emphasis on health and wellness, where appetite-suppressing medications are changing consumer habits. The anticipated decrease in alcohol demand presents challenges for retailers who have traditionally relied on beverage promotions to attract shoppers. Adaptations in store layouts and marketing strategies may follow as the market responds to evolving consumer preferences shaped by these pharmaceutical developments.